Indications |
Oral Reduction of the vascularity of the thyroid gland preoperatively Adult: 250 mg tid for 10-14 days before surgery. Alternatively, 0.1-0.3 ml strong iodine soln tid. Child: Same as adult dose. Oral Thyrotoxicosis Adult: 500 mg every 4 hr. Given 1 hr after an antithyroid agent. Oral Cutaneous or lymphocutaneous sporotrichosis Adult: 1 ml (1 g/ml) tid. Treatment should be continued for at least 1 mth after the disappearance or stabilisation of the lesions. Child: Max of 1.25-2 g tid. Usual duration of therapy is 3-6 months. Oral Radiation emergency Adult: >40 yr with a predicted thyroid exposure of ≥500 cGy, 18-40 yr with a predicted exposure of ≥10 cGy, pregnant or lactating women with a predicted exposure of ≥5 cGy, adolescents approaching adult size(≥70 kg) with a predicted exposure of ≥5 cGy: 130 mg daily until the risk of significant exposure to radioiodides either by inhalation or ingestion no longer exists. Child: 3-18 yr (except adolescents approaching adult size) with a predicted exposure of ≥5 cGy: 65 mg; 1 mth-3 yr with a predicted exposure of ≥5 cGy: 32 mg; infants from birth-1 mth with a predicted exposure of ≥ 5 cGy: 16 mg. Doses to be taken daily until the risk of significant exposure to radioiodides no longer exists. Oral Cough Adult: 300-650 mg 3-4 times daily. Child: 60-250 mg 4 times daily. |
Contraindications |
Hypersensitivity. Acute bronchitis. |
Warnings / Precautions |
Pregnancy, lactation. Hyperkalaemia, hyperthyroidism, myotonia congenita, renal function impairment, tuberculosis, hypocomplementemic vasculitis, goiter, autoimmune thyroid disease. Child. Repeated admin not recommended in neonatesdue to risk of hypothyroidism. |
Adverse Reactions |
Hypersensitivity reactions, gastric irritation, diarrhoea. Iodism (large doses). Potentially Fatal: Periarteritis. |
Drug Interactions |
Concurrent use with antithyroid agents may lead additional hypothyroid effect. Concurrent use with potassium-containing drugs or potassium-sparing diuretics may lead to hyperkalaemia. Potentially Fatal: Concurrent use with lithium salts may lead to additive hypothyroid effect. See Below for More potassium iodide Drug Interactions |
Lab Interactions |
Thyroid function test. |
Mechanism of Actions |
Potassium iodide participates in a complex series of reactions in the thyroid gland to produce thyroid hormones. When used for hyperthyroidism, it rapidly inhibits the release of thyroid hormones via a direct effect on the thyroid gland and inhibits the synthesis of thyroid hormones. Vascularity of the thyroid gland is reduced. When used in radiation emergencies, oral potassium iodide is admin before or promptly after intake of radioactive iodine, blocks thyroidal uptake of radioactive isotopes of iodine, thereby minimizing the risk of radiation-induced thyroid neoplasms. As an antifungal agent, it results in rapid cell destruction. Distribution: Crosses the placenta and distributes into the breast milk. Excretion: Iodides that are not taken up by the thyroid will be excreted mainly in the urine. |
Storage Conditions |
Oral: Store at 25°C. Protect from light. |
ATC Classification |
R05CA02 - potassium iodide ; Belongs to the class of expectorants. Used in the treatment of wet cough. S01XA04 - potassium iodide ; Belongs to the class of other ophthalmologicals. V03AB21 - potassium iodide ; Belongs to the class of antidotes. Used in the management of radioisotope and heavy metal poisoning. |
Storage |
Oral: Store at 25°C. Protect from light. |
Available As |
|
Potassium Iodate
Post Review about Potassium Iodate Click here to cancel reply.
Potassium Iodate Containing Brands
Potassium Iodate is used in following diseases
Drug - Drug Interactions of Potassium Iodate
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.